Therefore, any treatment that normalizes GH/IGF-I should improve insulin sensitivity and decrease glucose intolerance, provided that the treatment does not also decrease insulin secretion as well, as is the case with SSAs. This evidence concerns the gene IGF1 and Glucose intolerance.